Clinical trials
Prostate Cancer Recurrent clinical trials
Below are recruiting prostate cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 248 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07222436Recruiting
Blood test for high-risk prostate cancer
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07227077Recruiting
Physical activity study for older cancer survivors with chronic pain
This study uses a smartphone program to encourage physical activity in older adults who have survived cancer and have ongoing pain. It aims to learn how to best help you move more and feel better.
Milwaukee, WisconsinAges 65 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07150715RecruitingPhase 2
Radioactive drug plus precise radiation for recurrent prostate cancer
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
Los Angeles, CaliforniaAges 18 years+ - NCT05582876Recruiting
PET/MR scan to plan personalized prostate cancer treatment
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
BialystokAges 18–99 - NCT07131956Recruiting
Immune biomarkers in prostate cancer brachytherapy
This study looks at immune system markers in men getting brachytherapy (internal radiation) for prostate cancer. It may help us understand how the body responds to this treatment.
Augsburg, BavariaAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07115277Recruiting
A new imaging test for prostate cancer that has come back
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07073794RecruitingPhase 2
Home versus clinic cancer therapy for Black men with prostate cancer
This study looks at whether giving certain prostate cancer treatments at home (instead of the clinic) works as well for Black men. If you qualify, you may get your regular treatment at home with a nurse.
Jacksonville, FloridaAges 18 years+ - NCT07038304RecruitingPhase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
GroningenAges 18 years+ - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
Boston, MassachusettsAges 40 years+ - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06862856Recruiting
PET Scan for Men With Very Low PSA After Prostate Surgery
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06813898RecruitingEarly Phase 1
A New Scan for Early Prostate Cancer Recurrence
This study tests a new scanning method (rhPSMA-7.3 PET/CT) to detect prostate cancer recurrence when PSA is slightly high. If your PSA is low but rising, and standard scans haven't found cancer, this scan might help locate it.
Chicago, IllinoisAges Any age - NCT06654336RecruitingPhase 2
Targeted therapy with or without hormone therapy for prostate cancer that has spread a little
This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.
Hamilton, OntarioAges 18 years+ - NCT06650579RecruitingPhase 3
Heart safety study of relugolix vs leuprolide for prostate cancer
This trial compares two hormone therapy combinations for men with prostate cancer that hasn't spread. The goal is to see if a newer oral medication (Relugolix) plus abiraterone works better than the standard injectable therapy (Lupron) plus abiraterone, while also checking heart safety.
Atlanta, GeorgiaAges 18 years+ - NCT06508567Recruiting
MRI-Guided Internal Radiation for Returning Prostate Cancer
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
Toronto, OntarioAges 18 years+
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer recurrent?
- Yes. Clin2 currently lists 248 recruiting prostate cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.